ReviewJournal of internal medicine2021
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease.
Review in Journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05260177 (ALZLIGHT Stage III - Study on the Effect of 40 Hz Non-Invasive Light Therapy System), which is not on this map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ALZLIGHT Stage III - Study on the Effect of 40 Hz Non-Invasive Light Therapy System
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.Alzheimer's research & therapy · 2022Trial
- Novel cell markers with altered expression in brain aging and Alzheimer's disease: A review.IBRO neuroscience reports · 2026Article
- Antemortem α-Synuclein levels from neuron-derived extracellular vesicles identify Lewy Body pathology in Parkinson's Disease and Alzheimer Disease.medRxiv : the preprint server for health sciences · 2026Article
- Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Evaluation of Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid, Serum, and Plasma Using the Fully Automated Lumipulse Platform.Journal of clinical laboratory analysis · 2026Article
- CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.medRxiv : the preprint server for health sciences · 2026Article
- Psychophysiological effects of dance/movement therapy on anxiety reduction in adolescents in juvenile detention centers: dopamine and thermoregulatory responses in a controlled study.Child and adolescent psychiatry and mental health · 2026Article
- Association of plasma biomarkers with amyloid and tau PET in pre-dementia stages.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Evaluation of serum as an alternative matrix to plasma for NULISA‑based proteomic blood biomarker measurements.Scientific reports · 2026Article
- Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.Brain : a journal of neurology · 2026Article
- Blood-based biomarkers of Alzheimer's disease: potential utility in clinical practice.Current opinion in neurology · 2026Review
- Blood-based biomarkers for Alzheimer's disease diagnosis: a joint position paper from the Italian Societies of Neurology (SIN) and of Clinical Biochemistry and Clinical Molecular Biology - Laboratory Medicine(SIBioC) and from the Autonomous Association affiliated with SIN for dementia (SINdem).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Feasibility and validity of using self-collected capillary blood using Tasso+ for measuring Alzheimer's Disease plasma-based biomarkers among underrepresented populations.medRxiv : the preprint server for health sciences · 2026Article
- FDA approval of the Lumipulse G PTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis.Annals of medicine and surgery (2012) · 2026Article
- Longitudinal investigation of spatial memory and retinal parameters in a 5xFAD model of Alzheimer's disease reveals differences dependent on genotype and sex.Biomedical optics express · 2026Article
- Paper-Based Microfluidic Devices: A Powerful Strategy for Rapid Detection.Micromachines · 2025Review
- Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease.European archives of psychiatry and clinical neuroscience · 2025Article
- Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platform.medRxiv : the preprint server for health sciences · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 3 countries.
Funding
Abstract
Alzheimer's disease (AD) is increasingly prevalent worldwide, and disease-modifying treatments may soon be at hand; hence, now, more than ever, there is a need to develop techniques that allow earlier and more secure diagnosis. Current biomarker-based guidelines for AD diagnosis, which have replaced the historical symptom-based guidelines, rely heavily on neuroimaging and cerebrospinal fluid (CSF) sampling. While these have greatly improved the diagnostic accuracy of AD pathophysiology, they are less practical for application in primary care, population-based and epidemiological settings, or where resources are limited. In contrast, blood is a more accessible and cost-effective source of biomarkers in AD. In this review paper, using the recently proposed amyloid, tau and neurodegeneration [AT(N)] criteria as a framework towards a biological definition of AD, we discuss recent advances in biofluid-based biomarkers, with a particular emphasis on those with potential to be translated into blood-based biomarkers. We provide an overview of the research conducted both in CSF and in blood to draw conclusions on biomarkers that show promise. Given the evidence collated in this review, plasma neurofilament light chain (N) and phosphorylated tau (p-tau; T) show particular potential for translation into clinical practice. However, p-tau requires more comparisons to be conducted between its various epitopes before conclusions can be made as to which one most robustly differentiates AD from non-AD dementias. Plasma amyloid beta (A) would prove invaluable as an early screening modality, but it requires very precise tests and robust pre-analytical protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.